Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40


Diffusion model comparison identifies distinct tumor sub-regions and tracks treatment response.

McHugh DJ, Lipowska-Bhalla G, Babur M, Watson Y, Peset I, Mistry HB, Hubbard Cristinacce PL, Naish JH, Honeychurch J, Williams KJ, O'Connor JPB, Parker GJM.

Magn Reson Med. 2020 Feb 14. doi: 10.1002/mrm.28196. [Epub ahead of print]


Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.

Vassileva V, Stribbling SM, Barnes C, Carroll L, Braga M, Abrahams J, Heinzmann K, Haegeman C, MacFarlane M, Simpson KL, Dive C, Honeychurch J, Illidge TM, Aboagye EO.

EJNMMI Res. 2019 Feb 19;9(1):18. doi: 10.1186/s13550-019-0487-8.


The influence of radiation in the context of developing combination immunotherapies in cancer.

Honeychurch J, Illidge TM.

Ther Adv Vaccines Immunother. 2017 Dec;5(6):115-122. doi: 10.1177/2051013617750561. Epub 2018 Jan 24. Review.


Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.

Kordbacheh T, Honeychurch J, Blackhall F, Faivre-Finn C, Illidge T.

Ann Oncol. 2018 Feb 1;29(2):301-310. doi: 10.1093/annonc/mdx790. Review.


The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.

Walshaw RC, Honeychurch J, Illidge TM, Choudhury A.

Nat Rev Urol. 2018 Apr;15(4):251-259. doi: 10.1038/nrurol.2017.172. Epub 2017 Oct 31. Review.


A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Oct;31(10):2278. doi: 10.1038/leu.2017.218. Epub 2017 Jul 28.


Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM.

Clin Cancer Res. 2017 Sep 15;23(18):5514-5526. doi: 10.1158/1078-0432.CCR-16-1673. Epub 2017 May 22.


Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?

Marshall R, Popple A, Kordbacheh T, Honeychurch J, Faivre-Finn C, Illidge T.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):207-217. doi: 10.1016/j.clon.2016.12.003. Epub 2017 Jan 4. Review.


A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28. Erratum in: Leukemia. 2017 Jul 28;:.


Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?

Walshaw RC, Honeychurch J, Illidge TM.

Br J Radiol. 2016 Oct;89(1066):20160472. doi: 10.1259/bjr.20160472. Epub 2016 Sep 14. Review.


Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J.

Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30.


Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928.


Erratum to: Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype.

Bowron A, Honeychurch J, Williams M, Tsai-Goodman B, Clayton N, Jones L, Shortland GJ, Qureshi SA, Heales SJ, Steward CG.

J Inherit Metab Dis. 2016 Jan;39(1):151. doi: 10.1007/s10545-015-9891-z. No abstract available.


Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.


Immuno-regulatory antibodies for the treatment of cancer.

Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM.

Expert Opin Biol Ther. 2015 Jun;15(6):787-801. doi: 10.1517/14712598.2015.1036737. Epub 2015 Apr 16. Review.


Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM.

Cancer Res. 2014 Oct 1;74(19):5458-68. doi: 10.1158/0008-5472.CAN-14-1258.


Update on obinutuzumab in the treatment of B-cell malignancies.

Illidge T, Cheadle EJ, Donaghy C, Honeychurch J.

Expert Opin Biol Ther. 2014 Oct;14(10):1507-17. doi: 10.1517/14712598.2014.948414. Epub 2014 Sep 5. Review.


Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype.

Bowron A, Honeychurch J, Williams M, Tsai-Goodman B, Clayton N, Jones L, Shortland GJ, Qureshi SA, Heales SJ, Steward CG.

J Inherit Metab Dis. 2015 Mar;38(2):279-86. doi: 10.1007/s10545-014-9747-y. Epub 2014 Aug 12. Erratum in: J Inherit Metab Dis. 2016 Jan;39(1):151.


A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ.

Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17.


New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor.

Illidge TM, Cheadle EJ, Honeychurch J.

Leuk Lymphoma. 2014 Jan;55(1):3-4. doi: 10.3109/10428194.2013.797976. Epub 2013 Oct 24. No abstract available.


Synchronous apoptosis in established tumors leads to the induction of adaptive immunity.

Honeychurch J, Dive C, Illidge TM.

Oncoimmunology. 2013 Jun 1;2(6):e24501. Epub 2013 Apr 16.


The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.

Cheadle EJ, Sidon L, Dovedi SJ, Melis MH, Alduaij W, Illidge TM, Honeychurch J.

Br J Haematol. 2013 Sep;162(6):842-5. doi: 10.1111/bjh.12427. Epub 2013 Jun 18. No abstract available.


Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response.

Melis MH, Simpson KL, Dovedi SJ, Welman A, MacFarlane M, Dive C, Honeychurch J, Illidge TM.

Cell Death Differ. 2013 May;20(5):765-73. doi: 10.1038/cdd.2013.8. Epub 2013 Feb 15.


Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

Honeychurch J, Melis MH, Dovedi SJ, Mu L, Illidge TM.

Leuk Lymphoma. 2013 Sep;54(9):2008-15. doi: 10.3109/10428194.2013.769219. Epub 2013 Feb 18.


Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM.

Blood. 2013 Jan 10;121(2):251-9. doi: 10.1182/blood-2012-05-432393. Epub 2012 Oct 18.


Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.

Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM.

Blood. 2012 Apr 12;119(15):3523-33. doi: 10.1182/blood-2011-12-395541. Epub 2012 Feb 21.


Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM.

Blood. 2011 Apr 28;117(17):4519-29. doi: 10.1182/blood-2010-07-296913. Epub 2011 Mar 4.


Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS.

J Clin Invest. 2009 Aug;119(8):2143-59. doi: 10.1172/JCI37884. Epub 2009 Jul 20.


Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy.

Du Y, Honeychurch J, Cragg MS, Bayne M, Glennie MJ, Johnson PW, Illidge TM.

Blood. 2004 Feb 15;103(4):1485-94. Epub 2003 Oct 23.


Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.

Honeychurch J, Glennie MJ, Johnson PW, Illidge TM.

Blood. 2003 Aug 15;102(4):1449-57. Epub 2003 Apr 24.


Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide.

Lee-MacAry AE, Ross EL, Davies D, Laylor R, Honeychurch J, Glennie MJ, Snary D, Wilkinson RW.

J Immunol Methods. 2001 Jun 1;252(1-2):83-92.


Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.

Illidge T, Honeychurch J, Vandersteen A, Cragg M.

Cancer Biother Radiopharm. 2000 Dec;15(6):581-91.


A new in vivo and in vitro B cell lymphoma model, pi-BCL1.

Illidge T, Honeychurch J, Howatt W, Ross F, Wilkins B, Cragg M.

Cancer Biother Radiopharm. 2000 Dec;15(6):571-80.


Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma.

Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ.

Blood. 2000 Nov 15;96(10):3544-52.


The application of monoclonal antibodies in the treatment of lymphoma.

Glennie MJ, Honeychurch J, French RR, Tutt AL.

Methods Mol Med. 2000;40:85-97. doi: 10.1385/1-59259-076-4:85.


Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.

Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, Fearon DT, Parkhouse RM, Klaus GG, Glennie MJ.

J Immunol. 1998 Sep 15;161(6):3176-85.


Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.

Honeychurch J, Cruise A, Tutt AL, Glennie MJ.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):171-3.


Supplemental Content

Loading ...
Support Center